Archives of pathology & laboratory medicine (Arch Pathol Lab Med)

Publisher: College of American Pathologists; American Medical Association, College of American Pathologists

Current impact factor: 2.84

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 2.838
2013 Impact Factor 2.884
2012 Impact Factor 2.781
2011 Impact Factor 2.577
2010 Impact Factor 2.279
2009 Impact Factor 2.558
2008 Impact Factor 2.527
2007 Impact Factor 1.806
2006 Impact Factor 1.605
2005 Impact Factor 1.587
2004 Impact Factor 1.698
2003 Impact Factor 1.281
2002 Impact Factor 1.41
2001 Impact Factor 1.257
2000 Impact Factor 1.432
1999 Impact Factor 1.417
1998 Impact Factor 1.193
1997 Impact Factor 1.542
1996 Impact Factor 1.674
1995 Impact Factor 1.644
1994 Impact Factor 1.436
1993 Impact Factor 1.23
1992 Impact Factor 1.206

Impact factor over time

Impact factor

Additional details

5-year impact 2.90
Cited half-life 9.10
Immediacy index 0.68
Eigenfactor 0.01
Article influence 0.88
Website Archives of Pathology and Laboratory Medicine website
Other titles Archives of pathology & laboratory medicine (Online), Archives of pathology & laboratory medicine, Archives of pathology and laboratory medicine
ISSN 1543-2165
OCLC 46788521
Material type Document, Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Computer File, Internet Resource

Publisher details

College of American Pathologists

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Conditions
    • Written permission must be obtained from the publisher
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract] ABSTRACT: Atypical fibroxanthoma is a malignant skin tumor with histologic features similar to those of undifferentiated pleomorphic sarcoma, but lacking its more aggressive behavior. The tumor is composed of pleomorphic cells with hyperchromatic nuclei and abundant cytoplasm, commonly arranged in a spindle cell pattern. Recent genetic studies have identified similarities between atypical fibroxanthoma and undifferentiated pleomorphic sarcoma, such as the presence of 9p and 13q deletions in both tumors, favoring a common histogenesis. However, the lack of K-ras and H-ras mutations in atypical fibroxanthoma compared with undifferentiated pleomorphic sarcoma could explain the difference in aggressiveness and continued separation of these entities. Exclusion of other neoplasms by histology and immunohistochemistry followed by complete surgical removal remains the standard of care.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are a continuum of lung changes arising from a wide variety of lung injuries, frequently resulting in significant morbidity and frequently in death. Research regarding the molecular pathophysiology of ALI/ARDS is ongoing, with the aim toward developing prognostic molecular biomarkers and molecular-based therapy. Objective: -To review the clinical, radiologic, and pathologic features of ALI/ARDS; and the molecular pathophysiology of ALI/ARDS, with consideration of possible predictive/prognostic molecular biomarkers and possible molecular-based therapies. Data sources: -Examination of the English-language medical literature regarding ALI and ARDS. Conclusions: -ARDS is primarily a clinicoradiologic diagnosis; however, lung biopsy plays an important diagnostic role in certain cases. A significant amount of progress has been made in the elucidation of ARDS pathophysiology and in predicting patient response, however, currently there is no viable predictive molecular biomarkers for predicting the severity of ARDS, or molecular-based ARDS therapies. The proinflammatory cytokines TNF-α (tumor necrosis factor α), interleukin (IL)-1β, IL-6, IL-8, and IL-18 are among the most promising as biomarkers for predicting morbidity and mortality.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Landmark events in the field of lung cancer in the past year have the potential to significantly alter the practice of pathology. Three key events are (1) approval of payment for low-dose computed tomography screening for lung cancer, (2) publication of an extensively revised World Health Organization classification of lung cancers, and (3) approval of immunohistochemistry based companion diagnostics by the US Food and Drug Administration. We briefly review these milestones in the context of their impact on the practice of pathology.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -Gastrointestinal (GI) and pancreatobiliary tracts contain a variety of neuroendocrine cells that constitute a diffuse endocrine system. Neuroendocrine tumors (NETs) from these organs are heterogeneous tumors with diverse clinical behaviors. Recent improvements in the understanding of NETs from the GI and pancreatobiliary tracts have led to more-refined definitions of the clinicopathologic characteristics of these tumors. Under the 2010 World Health Organization classification scheme, NETs are classified as grade (G) 1 NETs, G2 NETs, neuroendocrine carcinomas, and mixed adenoneuroendocrine carcinomas. Histologic grades are dependent on mitotic counts and the Ki-67 labeling index. Several new issues arose after implementation of the 2010 World Health Organization classification scheme, such as issues with well-differentiated NETs with G3 Ki-67 labeling index and the evaluation of mitotic counts and Ki-67 labeling. Hereditary syndromes, including multiple endocrine neoplasia type 1 syndrome, von Hippel-Lindau syndrome, neurofibromatosis 1, and tuberous sclerosis, are related to NETs of the GI and pancreatobiliary tracts. Several prognostic markers of GI and pancreatobiliary tract NETs have been introduced, but many of them require further validation. Objective: -To understand clinicopathologic characteristics of NETs from the GI and pancreatobiliary tracts. Data sources: -PubMed (US National Library of Medicine) reports were reviewed. Conclusions: -In this review, we briefly summarize recent developments and issues related to NETs of the GI and pancreatobiliary tracts.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -The traceability of clinical results to internationally recognized and accepted reference materials and reference measurement procedures has become increasingly important. Therefore, the establishment of traceability has become a mandatory requirement for all in vitro diagnostics devices. Objectives: -To evaluate the traceability of the Abbott Architect c8000 system (Abbott Laboratories, Abbott Park, Illinois), consisting of calibrators and reagents, across 4 different chemistry analyzers, and to evaluate its general performance on the Toshiba 2000FR NEO (Toshiba Medical Systems Corporation, Otawara-shi, Tochigi-ken, Japan). Design: -For assessment of traceability, secondary reference materials were evaluated 5 times, and then bias was calculated. Precision, linearity, and carryover were determined according to the guidelines of the Clinical and Laboratory Standards Institute (Wayne, Pennsylvania). Results: -The biases from 4 different analyzers ranged from -2.33% to 2.70% on the Toshiba 2000FR NEO, -2.33% to 5.12% on the Roche Hitachi 7600 (Roche Diagnostics International, Basel, Switzerland), -0.93% to 2.87% on the Roche Modular, and -2.16% to 2.86% on the Abbott Architect c16000. The total coefficients of variance of all analytes were less than 5%. The coefficients of determination (R(2)) were more than 0.9900. The carryover rate ranged from -0.54% to 0.17%. Conclusions: -Abbott clinical chemistry assays met the performance criteria based on desirable biological variation for precision, bias, and total error. They also showed excellent linearity and carryover. Therefore, these clinical chemistry assays were found to be accurate and reliable and are readily applicable on the various platforms used in this study.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Liposclerosing myxofibrous tumor is a benign fibro-osseous lesion, with distinct radiographic and clinical features and diverse histologic patterns. This lesion occurs in the fourth decade of life, with equal male and female incidence. Most lesions are discovered incidentally, but patients can present with bone pain or fracture. Liposclerosing myxofibrous tumor exhibits a very strong predilection for the proximal femur with characteristic radiographic findings, often providing an initial clue to diagnosis. Microscopically, this tumor is characterized by a variety of patterns, including myxofibrous tissue, fibrous dysplasia-like features, and ischemic ossification. It can be mistaken for many other fibro-osseous lesions; therefore, this unique lesion should be included in the differential diagnosis of fibro-osseous lesions, particularly in this location. Patients with this lesion are generally successfully treated by curettage and bone graft and have a favorable prognosis. A small risk of malignant transformation has been suggested to be associated with these lesions. This necessitates the need for follow-up monitoring of this entity. In this review, we discuss current knowledge of this lesion and its clinical relevance.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain differentiation, initially described by Enzinger and colleagues. Until now, nearly 300 such cases have been reported worldwide. The histogenesis of these tumors remains controversial. These tumors show characteristic imaging findings and exhibit a spectrum of histopathologic features, including classical and atypical subtypes. Local recurrences and, occasionally, distant metastases have also been reported. A complete tumor resection forms the preferred treatment modality for these tumors, along with follow-up, as these tumors have an uncertain malignant potential. Lately, certain "molecular signatures" underlying OFMTs have been described that can further aid in reaching an accurate diagnosis for these tumors and unraveling their pathogenesis. This article is a review of the clinical, radiologic, histopathologic, and molecular features of OFMTs.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -Jejunoileal neuroendocrine tumors (JINETs) are slow-growing, malignant tumors that are often associated with protracted survival, despite their frequent presentation at an advanced stage. A subset of JINETs is complicated by intestinal ischemic necrosis (IIN), which leads to their initial clinical presentation. Objective: -To assess the effect of IIN on overall survival in patients with JINETs. Design: -Ten JINETs with IIN during a 14-year period and a control group of 52 JINETs without IIN were identified retrospectively. The hematoxylin-eosin slides and gross descriptions were reviewed, and pathologic features were assessed. Overall survival was compared between the 2 groups using the Kaplan Meier method and Cox proportional hazards model. Results: -At 1 year postresection, only 40% (4 of 10) of the patients with IIN were alive, whereas 94% (49 of 52) of those without IIN were alive (P < .001). Patients with IIN were significantly older than those without IIN (median, 83 years versus 65.5 years, P = .001). By univariate Cox proportional hazards regression, IIN was associated with a 4.30-fold increased risk of death (95% confidence interval 1.75-10.56; P = .001). When controlling for age, advanced stage (stage III or IV), tumor grade, and synchronous carcinoma in a multivariate analysis, IIN showed a trend toward prognostic significance (2.31-fold increased risk of death; 95% confidence interval, 0.85-6.27; P = .10). Conclusions: -The pathologic identification of tumor-associated IIN portends a worse overall survival among patients with JINETs.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -TTF-1 and napsin A immunomarkers have a crucial role in differentiating lung adenocarcinoma from lung squamous cell carcinoma and in identifying a primary lung adenocarcinoma when working on a tumor of unknown origin. Objectives: -To investigate the diagnostic sensitivity of ribonucleic acid in situ hybridization (RNAscope) in the detection of expression of these biomarkers in lung adenocarcinomas and to compare RNAscope to immunohistochemical techniques. Design: -Both RNAscope and the immunohistochemical assays for TTF-1 and napsin A were performed on tissue microarray sections containing 80 lung adenocarcinomas and 80 lung squamous cell carcinomas. The RNAscope assay for both TTF-1 and napsin A was also performed on 220 adenocarcinomas from various organs. Results: -The RNAscope assay for TTF-1 gave positive results in 92.5% (74 of 80) of the lung adenocarcinomas; in contrast, immunohistochemistry gave positive results in 82.5% (66 of 80) of those cases. The RNAscope assay for napsin A gave positive results in 90% (72 of 80) of lung adenocarcinomas; immunohistochemistry results were positive in 77.5% (62 of 80) of those cases. Napsin A expression was not seen in lung squamous cell carcinomas by either method. In contrast, TTF-1 expression was seen in 3.8% (3 of 80) (1(+)) and 10% (8 of 80) (1(+)) of the squamous cell carcinomas by immunochemistry and the RNAscope, respectively. All nonpulmonary adenocarcinoma results were negative for TTF-1 by the RNAscope assay. Conclusions: -Preliminary data suggest that RNAscope is superior to immunohistochemistry in detecting TTF-1 and napsin A expression in primary lung adenocarcinomas. Therefore, performing an RNAscope assay may be considered for both TTF-1(-) and napsin A(-) cases with a clinical suspicion of lung adenocarcinoma. The TTF-1 results should be interpreted with caution because a small percentage of squamous cell carcinomas can be focally positive by either assay.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective: -To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data sources: -Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions: -Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -Although epidermal growth factor receptor (EGFR)- and anaplastic lymphoma kinase (ALK)-directed therapies are not approved for patients with early-stage non-small cell lung carcinoma (NSCLC), many institutions perform EGFR and ALK testing for all patients with NSCLC at the time of initial diagnosis. Current consensus guidelines recommend EGFR testing and suggest ALK testing at the time of initial diagnosis for patients with advanced disease. Objectives: -To examine the cost and clinical impact of EGFR and ALK testing of patients with early-stage NSCLC. Design: -Records from all patients with a diagnosis of NSCLC made on a nonresection specimen at our institution during a single calendar year (2012) were reviewed, and a cost analysis was performed. Results: -Of 133 total patients, 47 (35%) had early-stage (stage I or II) disease and 86 (65%) had locally advanced (stage III) or advanced (stage IV) disease at presentation. Eight of 47 patients with early-stage disease (17%) had progression/recurrence during 18 to 30 months of follow-up, 6 of 8 (75%) of whom had pathologic confirmation of progression/recurrence. The estimated additional cost of EGFR and ALK testing for all newly diagnosed patients with NSCLC at our institution is $75 200 per year, compared to testing only patients with locally advanced and advanced-stage disease. Conclusions: -The cost of universal molecular testing of NSCLC is substantial. EGFR and ALK testing of patients with early-stage disease appears to have negligible clinical impact, as most patients do not have disease recurrence/progression. Those whose disease recurs/progresses typically undergo rebiopsy. Our findings do not support the practice of universal EGFR and ALK testing in NSCLC at the time of initial diagnosis.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • No preview · Article · May 2016 · Archives of pathology & laboratory medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Context: -The diagnosis of gastric epithelial lesions is difficult in clinical practice, even with the recent developments and advances in endoscopic modalities, owing to the diverse morphologic features of the lesions, lack of standardized diagnostic criteria, and the high intraobserver and interobserver variabilities in the nonneoplastic (regenerative)-neoplastic spectrum. Objective: -To provide an overview of the current concepts and unresolved issues surrounding the diagnosis of diseases in the nonneoplastic-neoplastic spectrum, and to discuss some noteworthy properties and histologic features of gastric epithelial lesions. Data sources: -A comprehensive assessment of the medical literature on gastric epithelial lesions was performed; we also interjected our own experiences into the discussion. Sources included original studies, review articles, and textbooks related to the field. Conclusions: -Our literature review revealed that clear cell changes and micropapillary carcinoma components in gastric carcinomas are associated with poor clinical outcomes and should hence be included in pathologic reports. Moreover, we suggest a stepwise biopsy-endoscopic resection modality for the diagnosis of borderline neoplasia-nonneoplasia cases.
    No preview · Article · May 2016 · Archives of pathology & laboratory medicine